uniQure NV
Fechado
44.72 1.08
Visão Geral
Variação de preço das ações
24h
Mín
44.19
Máximo
45
Rendimento | -28M -81M |
|---|---|
Vendas | 2.3M 5.8M |
EPS | -1.22 |
Margem de lucro | -1,387.759 |
Funcionários | 221 |
EBITDA | -34M -70M |
Próximos Ganhos | 9 de nov. de 2026 |
|---|
Capitalização de Mercado | 460M 3.1B |
|---|---|
Abertura anterior | 43.64 |
Fecho anterior | 44.72 |
uniQure NV Gráfico
O desempenho passado não é um indicador confiável de resultados futuros.
Notícias Relacionadas
Comparação entre Pares
Variação de preço
uniQure NV Previsão
Informação Financeira
Custos administrativos e de venda
Custos Operacionais
Lucro antes de imposto
Vendas
Custo das vendas
Lucro bruto sobre vendas
Despesa com juros da dívida
EBITDA
Resultado Operacional
$
Sobre uniQure NV
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.